188 related articles for article (PubMed ID: 32882004)
1. Integrin VLA-4 as a PET imaging biomarker of hyper-adhesion in transgenic sickle mice.
Perkins LA; Nyiranshuti L; Little-Ihrig L; Latoche JD; Day KE; Zhu Q; Tavakoli S; Sundd P; Novelli EM; Anderson CJ
Blood Adv; 2020 Sep; 4(17):4102-4112. PubMed ID: 32882004
[TBL] [Abstract][Full Text] [Related]
2. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.
Beaino W; Anderson CJ
J Nucl Med; 2014 Nov; 55(11):1856-63. PubMed ID: 25256059
[TBL] [Abstract][Full Text] [Related]
3. Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.
Soodgupta D; Zhou H; Beaino W; Lu L; Rettig M; Snee M; Skeath J; DiPersio JF; Akers WJ; Laforest R; Anderson CJ; Tomasson MH; Shokeen M
J Nucl Med; 2016 Apr; 57(4):640-5. PubMed ID: 26742713
[TBL] [Abstract][Full Text] [Related]
4. PET Imaging of VLA-4 in a New BRAF
Bellavia MC; Nyiranshuti L; Latoche JD; Ho KV; Fecek RJ; Taylor JL; Day KE; Nigam S; Pun M; Gallazzi F; Edinger RS; Storkus WJ; Patel RB; Anderson CJ
Mol Imaging Biol; 2022 Jun; 24(3):425-433. PubMed ID: 34694528
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors.
Jiang M; Ferdani R; Shokeen M; Anderson CJ
Nucl Med Biol; 2013 Feb; 40(2):245-51. PubMed ID: 23265977
[TBL] [Abstract][Full Text] [Related]
6. Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.
Soodgupta D; Hurchla MA; Jiang M; Zheleznyak A; Weilbaecher KN; Anderson CJ; Tomasson MH; Shokeen M
PLoS One; 2013; 8(2):e55841. PubMed ID: 23409060
[TBL] [Abstract][Full Text] [Related]
7. VLA-4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow.
White J; Krishnamoorthy S; Gupta D; Lancelot M; Moore N; Sarnaik S; Hobbs WE; Light DR; Hines P
Br J Haematol; 2016 Sep; 174(6):970-82. PubMed ID: 27291690
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Al
Gai Y; Yuan L; Sun L; Li H; Li M; Fang H; Altine B; Liu Q; Zhang Y; Zeng D; Lan X
J Biol Inorg Chem; 2020 Feb; 25(1):99-108. PubMed ID: 31745667
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging of very late antigen-4 (α4β1 integrin) in the premetastatic niche.
Shokeen M; Zheleznyak A; Wilson JM; Jiang M; Liu R; Ferdani R; Lam KS; Schwarz JK; Anderson CJ
J Nucl Med; 2012 May; 53(5):779-86. PubMed ID: 22496586
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.
Beaino W; Nedrow JR; Anderson CJ
Mol Pharm; 2015 Jun; 12(6):1929-38. PubMed ID: 25919487
[TBL] [Abstract][Full Text] [Related]
11. Preliminary evaluation of
Roxin Á; Zhang C; Huh S; Lepage ML; Zhang Z; Lin KS; Bénard F; Perrin DM
Nucl Med Biol; 2018 Jun; 61():11-20. PubMed ID: 29597141
[TBL] [Abstract][Full Text] [Related]
12. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
[TBL] [Abstract][Full Text] [Related]
13. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.
Styles LA; Lubin B; Vichinsky E; Lawrence S; Hua M; Test S; Kuypers F
Blood; 1997 Apr; 89(7):2554-9. PubMed ID: 9116302
[TBL] [Abstract][Full Text] [Related]
14. Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury.
Haddad J; Latoche JD; Nigam S; Bellavia MC; Day KE; Zhu Q; Edwards WB; Anderson CJ; Tavakoli S
J Nucl Med; 2021 Feb; 62(2):280-286. PubMed ID: 32680928
[TBL] [Abstract][Full Text] [Related]
15. Positron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α4β1-Expressing Immune Cells.
Mattila JT; Beaino W; Maiello P; Coleman MT; White AG; Scanga CA; Flynn JL; Anderson CJ
J Immunol; 2017 Jul; 199(2):806-815. PubMed ID: 28592427
[TBL] [Abstract][Full Text] [Related]
16. The alpha4beta1 integrin in sickle cell disease.
Brittain JE; Parise LV
Transfus Clin Biol; 2008; 15(1-2):19-22. PubMed ID: 18501656
[TBL] [Abstract][Full Text] [Related]
17. Cross-sectional analysis of adhesion in individuals with sickle cell disease using a standardized whole blood adhesion bioassay to VCAM-1.
White J; Lancelot M; Gao X; McGraw BJ; Tabb C; Hines P
Blood Cells Mol Dis; 2020 Mar; 81():102397. PubMed ID: 31864103
[TBL] [Abstract][Full Text] [Related]
18. Visualizing γδ T cells by very late antigen-4-targeted positron emission tomography.
Long Y; Lv X; Song X; Shao F; Ji H; Zhang Y; Qiao P; Liu Q; Xia X; Lei P; Gai Y; Lan X
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4156-4170. PubMed ID: 35790537
[TBL] [Abstract][Full Text] [Related]
19. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease.
Belcher JD; Chen C; Nguyen J; Milbauer L; Abdulla F; Alayash AI; Smith A; Nath KA; Hebbel RP; Vercellotti GM
Blood; 2014 Jan; 123(3):377-90. PubMed ID: 24277079
[TBL] [Abstract][Full Text] [Related]
20. An innovative intervention for the prevention of vaso-occlusive episodes in sickle cell disease.
Jeon WJ; Joung B; Moon JH; Hino C; Park D; Pham B; Castillo DR; Chong E; Kaur S; Grismore C; Cao H
Hematology; 2023 Dec; 28(1):2215575. PubMed ID: 37227254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
